BioCentury
ARTICLE | Clinical News

FDA accepts NDA for Insys' buprenorphine sublingual spray

December 8, 2017 4:20 AM UTC

Insys Therapeutics Inc. (NASDAQ:INSY) said FDA accepted for review an NDA for the company’s buprenorphine sublingual spray to manage moderate to severe acute pain. The PDUFA date is July 28, 2018...

BCIQ Company Profiles

Insys Therapeutics Inc.